National Bank of Canada FI Has $105.19 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

National Bank of Canada FI boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 161.8% during the fourth quarter, Holdings Channel reports. The fund owned 116,227 shares of the biopharmaceutical company’s stock after purchasing an additional 71,838 shares during the period. National Bank of Canada FI’s holdings in Regeneron Pharmaceuticals were worth $105,185,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after purchasing an additional 590,314 shares during the period. abrdn plc raised its position in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Regeneron Pharmaceuticals by 129.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after acquiring an additional 122,103 shares during the period. Finally, TD Asset Management Inc lifted its stake in Regeneron Pharmaceuticals by 64.4% during the third quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock worth $148,353,000 after purchasing an additional 70,628 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $19.39 during trading hours on Friday, hitting $957.00. The stock had a trading volume of 547,373 shares, compared to its average volume of 509,442. The company has a quick ratio of 4.94, a current ratio of 6.40 and a debt-to-equity ratio of 0.10. The stock has a market cap of $105.04 billion, a PE ratio of 28.27, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company’s fifty day simple moving average is $943.75 and its 200 day simple moving average is $897.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the business earned $10.96 EPS. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on REGN. UBS Group raised their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Barclays boosted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $977.77.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,095 shares of company stock valued at $9,664,476. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.